Acute Interstitial Pneumonia Overview

Save information for later
Sign Up

Learn About Acute Interstitial Pneumonia

What is the definition of Acute Interstitial Pneumonia?
Acute interstitial pneumonia (AIP) is a rare and serious condition that affects the lungs. The signs and symptoms generally develop and progress rapidly. In the early stages of the condition, affected people may experience upper respiratory and/or viral-like symptoms such as cough, shortness of breath, and fever. This is followed by the rapid onset of respiratory failure and the need for mechanical ventilation in the majority of cases. The underlying cause of AIP is unknown. Most cases occur sporadically in people with no family history of the condition.
What are the alternative names for Acute Interstitial Pneumonia?
  • Acute interstitial pneumonia
  • Acute interstitial pneumonitis
  • Hamman-Rich syndrome
Who are the top Acute Interstitial Pneumonia Local Doctors?
Dr. Robert M. Jackson
Pulmonary Medicine | Intensive Care Medicine
Dr. Robert M. Jackson
Pulmonary Medicine | Intensive Care Medicine

University Of Miami

1601 Nw 12th Ave, 
Miami, FL 
 (6.1 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Jackson is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Miami, Florida. Dr. Jackson and is rated as a Distinguished provider by MediFind in the treatment of Acute Interstitial Pneumonia. His top areas of expertise are Acute Interstitial Pneumonia, Pneumonia, Interstitial Lung Disease, and Idiopathic Pulmonary Fibrosis. Dr. Jackson is currently accepting new patients.

Dr. Andres F. Pelaez-Freidel
Pulmonary Medicine | Intensive Care Medicine
Dr. Andres F. Pelaez-Freidel
Pulmonary Medicine | Intensive Care Medicine

University Of Miami

1475 Nw 12th Ave, 
Miami, FL 
 (6.2 mi)
305-689-8648
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Andres Pelaez-Freidel is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Miami, Florida. Dr. Pelaez-Freidel and is rated as a Distinguished provider by MediFind in the treatment of Acute Interstitial Pneumonia. His top areas of expertise are Acute Interstitial Pneumonia, Interstitial Lung Disease, Pneumonia, Lung Metastases, and Lung Transplant. Dr. Pelaez-Freidel is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Dr. Eduardo G. Martinez
Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine
Dr. Eduardo G. Martinez
Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine
4051 E 8th Ave, Suite 3, 
Hialeah, FL 
 (0.7 mi)
305-835-9090
Languages Spoken:
English

Eduardo Martinez is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Hialeah, Florida. Dr. Martinez and is rated as an Experienced provider by MediFind in the treatment of Acute Interstitial Pneumonia. His top areas of expertise are Lung Metastases, Pneumonia, Chronic Obstructive Pulmonary Disease (COPD), and Interstitial Lung Disease.

View All Doctors
What are the latest Acute Interstitial Pneumonia Clinical Trials?
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial Evaluating the Efficacy and Safety of 2 Doses of Buloxibutid Over 52 Weeks in People With Idiopathic Pulmonary Fibrosis.
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial Evaluating the Efficacy and Safety of 2 Doses of Buloxibutid Over 52 Weeks in People With Idiopathic Pulmonary Fibrosis.
Enrollment Status: Recruiting
Publish Date: February 26, 2025
Intervention Type: Drug
Study Phase: Phase 2

Summary: The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF. Trial website: www.aspire-ipf.com

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis
Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis
Enrollment Status: Recruiting
Publish Date: February 26, 2025
Intervention Type: Procedure, Drug
Study Phase: Phase 2

Summary: This phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that is growing, spreading, or getting worse (progressive), has come back (relapsed) after previous treatment, or does not respond to therapy (refractory). Langerhans cell histiocytosis is a type of disease that occurs when the body makes too ma...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center